

# **Company report**

## AmInvestment Bank

Team Coverage

03-2036 2290

Rationale for report: Company results

Losses widened in 1QFY23

(TOPG MK EQUITY, TPGC.KL)

## Investment Highlights

TOP GLOVE CORP

RM0.785 Price Fair Value RM0.60 52-week High/Low RM2.59/RM0.57 **Key Changes** Fair value ⇔ EPS 0 YE to Aug FY22 FY23F FY24F FY25F 9,623.2 Revenue (RM mil) 5,458.2 7,644.1 5.572.5 Core net profit (RM mil) 408.0 (132.2)245.2 313.2 FD Core EPS (sen) 5.1 (1.7)3.1 3.9 FD Core EPS growth (%) (94.7) (132.4) (285.5) 27.7 Consensus Net Profit (RM mil) 175.7 312.9 414.8 DPS (sen) 1.2 0.0 2.0 2.0 PE (x) 15.4 25.6 20.1 nm EV/EBITDA (x) 7.2 26.5 8.3 7.1 Div yield (%) 1.5 (0.0)2.5 2.5 ROE (%) 4.1 (2.4)4.4 5.5 Net Gearing (%) nm nm nm nm Stock and Financial Data Shares Outstanding (million) 8.007.3 Market Cap (RMmil) 6,285.7 Book Value (RM/share) 0.70 P/BV (x) 1.1 ROE (%) 4.1 Net Gearing (%) nm Major Shareholders Tan Sri Dr Lim Wee Chai (34.7%) EPF (4.9%) OCBC Ltd (2.8%) Free Float 44.2% Avg Daily Value (RMmil) 65.0 Price performance 3mth 6mth 12mth

 Absolute (%)
 (23.8)
 (60.8)

 Relative (%)
 (1.0)
 (23.9)
 (60.8)



We maintain our SELL call on Top Glove Corporation (Top Glove) with an unchanged fair value (FV) of RM0.60/share. This is pegged to a target FY24F PE of 20x, at parity to its 10-year average. There is no ESG-related FV adjustment based on our unchanged 3-star rating.

- Top Glove reported a 1QFY23 core net loss of RM134mil. This was below our expectations of a net loss of RM48.6mil for FY23F and consensus, which had predicted a net profit of RM176mil.
- The deviation came mainly from weaker than expected selling prices and demand, which resulted in a sub-optimal plant utilisation rate (PU).
- We are now expecting Top Glove to record a larger FY23F core net loss of RM132mil vs. RM48.6mil previously. We have reduced our assumptions on Top Glove's average selling price (ASP) and PU. However, we retain our FY24-25F earnings forecasts for Top Glove in view of improving supply and demand dynamics.
- No interim dividend has been declared this quarter, which is in line with our assumption. Top Glove has halted dividend payments in the short-term to preserve its cash reserves.
- On a QoQ basis, Top Glove registered a larger 1QFY23 core net loss of RM134mil (-7.6x) in tandem with the 36% drop in revenue. The weaker revenue was mainly due to an 8% decline in ASP and lower sales orders (-32%) as a result of customers holding off restocking activities. Losses also widened QoQ in 1QFY23 dragged by rising costs of gas, electricity and labour.
- The blended ASP was US\$21.5-22.5/1K pcs in 1QFY23, 8% lower than 4QFY22 (Exhibit 2). This was mainly due to aggressive pricing from local and regional competitors.
- Based on our channel checks, Malaysian glove makers are selling normal nitrile medical gloves at an ASP of US\$17-19/1K pcs in Dec vs. Chinese glove makers' US\$14-15/1K pcs (or US\$15-16/1K pcs inclusive of the 7.5% US-tariff). This implies that there could be further downside of US\$2-3/1K pcs for nitrile medical gloves.
- Top Glove's plant operated at a lower utilisation rate of 30% in 1QFY23 compared to 30-40% in 4QFY22 and 85-90% pre-pandemic (Exhibit 3). On a positive note, Top Glove received healthy orders for Dec 2022 and Jan 2023, which could increase the PU to 40%.

## 15 Dec 2022


SELL

(Maintained)


- Top Glove's EBITDA swung into the red in 1QFY23 due to the sub-optimal PU, which increased the unit cost of production. Going forward, we believe that Top Glove would be focusing on improving the utilisation rate of its plant instead of raising prices. We reckon that this would result in stiff price competition as other glove makers in Malaysia try to maintain their market share.
- On a positive note, Top Glove guided that the customer replenishment cycle will take place from 2QCY23 onwards as inventories are depleting. This would increase the PU by 10 to 20 percentage points.
- The stock currently trades at a FY24F PE of 25x, which is 25% above its 10-year average. We believe this is unjustified in view of ongoing challenges remain unabated.

EXHIBIT 1: RESULTS SUMMARY							
FYE Dec (RM mil)	1QFY22	2QFY22	3QFY22	4QFY22	1QFY23	QoQ (%)	YoY (%)
Turnover	1,584.1	1,449.3	1,464.6	990.1	632.5	(36.1)	(60.1)
Operating costs	(1,207.3)	(1,191.5)	(1,307.4)	(996.5)	(664.3)	33.3	45.0
EBITDA	376.8	257.8	157.2	77.9	(31.8)	(>100)	(>100)
Depreciation	(83.6)	(85.8)	(89.0)	(89.7)	(88.0)	1.9	(5.3)
EBIT	293.2	172.0	68.3	(11.8)	(119.8)	(>100)	(>100)
Net interest	7.5	4.9	3.1	4.0	2.4	(40.7)	(67.9)
-Interest expense	(1.1)	(0.9)	(1.0)	(1.3)	(1.9)	(42.5)	(78.0)
-Interest income	8.5	5.8	4.1	5.4	4.3	(19.9)	(49.5)
Profit before El	300.7	176.9	71.4	(7.7)	(117.4)	(>100)	(>100)
Exceptional item	41.2	65.0	30.9	34.9	34.1	(2.1)	(17.2)
Associates contribution	(0.6)	0.4	(2.0)	(1.4)	(0.1)	93.5	85.4
PBT	258.8	112.3	38.4	(44.0)	(151.6)	(>100)	(>100)
Tax	(56.5)	(9.9)	(9.1)	2.3	(6.0)	(>100)	89.4
Perpetual Sukuk	(12.8)	(13.2)	(12.4)	(11.7)	(11.6)	1.1	9.2
MI	(3.9)	(1.6)	(1.6)	0.9	1.0	11.7	126.1
Net Profit	185.7	87.5	15.3	(52.6)	(168.2)	(>100)	(>100)
Core Net Profit	226.9	152.5	46.2	(17.7)	(134.1)	(>100)	(>100)
EPS (sen)	2.8	1.9	0.6	(0.2)	(1.6)	(>100)	(>100)
DPS (sen)	1.2	0.0	0.0	0.0	0.0	n/a	n/a
BV/share (RM)	0.7	0.7	0.7	0.7	0.7	(2.9)	(2.9)
Cash & Cash Equivalents	1,817.1	1,328.6	1,003.7	950.4	742.5	(21.9)	(59.1)
Borrowings	439.1	429.2	440.8	399.1	383.0	(4.0)	(12.8)
Equity ex Perpetual Sukuk & MI	5,609.7	5,621.4	5,644.4	5,590.3	5,421.2	(3.0)	(3.4)
Net cash/(debt)	1,378.0	899.4	562.9	551.3	359.5	(34.8)	(73.9)
EBITDA margin (%)	23.8	17.8	10.7	7.9	(5.0)	-12.9ppt	-28.8ppt
Pretax margin (%)	16.3	7.7	2.6	(4.4)	(24.0)	-19.5ppt	-40.3ppt
Effective tax rate (%)	21.8	8.9	23.7	5.2	(3.9)	-9.2ppt	-25.8ppt
Net profit margin (%)	11.7	6.0	1.0	(1.8)	(26.6)	-24.8ppt	-38.3ppt


Source: AmInvestment Bank/Bursa Malaysia/Top Glove



Source: Top Glove, AmInvestment Bank



Source: Top Glove, AmInvestment Bank






EXHIBIT 6: ESG MATRIX					
Overall	*	*	*		
Biological preservation	*	*			
Water + energy conservation	*	*			
Pollution + waste regulation	*	*			
Sustainable sourcing	*	*	*		
Occupational safety + health	*	*	*		
Workplace diversity	*	*	*		
Employee training + wellbeing	*	*	*		
Volunteering + charitable giving	*	*	*		
Corruption-free pledge	*	*	*		
Accessibility & transparency	*	*	*		

fundamental fair value based on the overall ESG rating as appraised by us, from 1-star to 5-stars

Source: AmInvestment Bank

EXHIBIT 7: FINANCIAL DATA							
ncome Statement (RMmil, YE 31 Aug)	FY21	FY22	FY23F	FY24F	FY25		
Revenue	16,361.4	5,572.5	5,458.2	7,644.1	9,623		
EBITDA	10,276.4	869.9	236.2	751.6	879		
Depreciation/Amortisation	(308.7)	(348.2)	(356.4)	(390.0)	(431.		
Derating income (EBIT)	9,967.8	521.7	(120.3)	361.5	448		
Other income & associates	2.6	(3.7)	(3.7)	(3.7)	(3.		
let interest	57.4	19.5	19.4	19.3	19		
Exceptional items	6.0	(172.0)	-	-			
Pretax profit	10,033.8	365.5	(104.6)	377.1	463		
axation	(2,209.8)	(73.2)	20.9	(75.4)	(92		
Ainorities/pref dividends	(62.3)	(6.1)	1.7	(6.3)	(7		
let profit	7,710.3	236.0	(132.2)	245.2	313		
Core net profit	7,704.3	408.0	(132.2)	245.2	313		
Balance Sheet (RMmil, YE 31 Aug)	FY21	FY22	FY23F	FY24F	FY2		
ixed assets	4,169.4	4,709.1	4,366.7	4,588.2	4,927		
ntangible assets	1,008.8	1,005.3	1,005.3	1,005.3	1,005		
Other long-term assets	258.5	259.5	259.5	259.5	259		
otal non-current assets	5,436.7	5,973.9	5,631.6	5,853.1	6,191		
Cash & equivalent	878.4	444.1	457.4	471.1	485		
Stock	1,144.7	564.0	825.6	1,083.6	1,368		
Trade debtors	566.3	236.1	576.2	737.4	870		
Other current assets	1,756.3	847.2	697.4	378.5	38		
otal current assets	4,345.8	2,091.4	2,556.5	2,670.7	2,76		
rade creditors	<b>4,343.0</b> 692.4	426.4	677.4	877.7	1,100		
Short-term borrowings	312.7	306.1	324.5	344.0	364		
Other current liabilities							
	1,193.4	209.3	111.6	139.1	17(		
otal current liabilities	2,198.5	941.8	1,113.5	1,360.8	1,641		
ong-term borrowings	146.0	93.0	95.8	98.6	10		
Other long-term liabilities	217.8	225.9	226.4	226.8	227		
otal long-term liabilities	363.8	318.9	322.1	325.4	328		
Shareholders' funds	5,872.4	5,590.3	5,538.2	5,623.3	5,776		
Minority interests	1,295.3	1,175.7	1,175.7	1,175.7	1,175		
3V/share (RM)	0.73	0.70	0.69	0.70	0.		
Cash Flow (RMmil, YE 31 Aug)	FY21	FY22	FY23F	FY24F	FY2		
Pretax profit	10,033.8	365.5	(104.6)	377.1	463		
Depreciation/Amortisation	308.7	348.2	356.4	390.0	43		
Net change in working capital	(324.9)	573.0	(298.7)	127.2	175		
Others	(2,190.7)	(1,151.1)	397.9	(117.5)	(135		
Cash flow from operations	7,826.9	135.5	351.1	776.8	934		
Capital expenditure	(1,348.6)	(918.9)	(436.7)	(611.5)	(769		
Vet investments & sale of fixed assets	-	-	-	-			
Others	100.7	1,090.7	2.5	-			
Cash flow from investing	(1,247.9)	171.8	(434.2)	(611.5)	(769		
Debt raised/(repaid)	27.1	(18.9)	7.8	8.6	ç		
Equity raised/(repaid)	-	-	-	-			
Dividends paid	(5,214.0)	(96.1)	80.1	(160.1)	(160		
Others	(1,716.1)	(625.3)	-	-			
Cash flow from financing	(6,903.0)	(740.3)	87.9	(151.5)	(150		
Net cash flow	(323.9)	(433.0)	4.8	13.7	14		
let cash/(debt) b/f	1,209.5	885.6	452.6	457.4	471		
let cash/(debt) c/f	885.6	452.6	457.4	471.1	48		
Cey Ratios (YE 31 Aug)	FY21	FY22	FY23F	FY24F	FY2		
Revenue growth (%)	126.1	(65.9)	(2.1)	40.0	25		
BITDA growth (%)	324.1	(91.5)	(72.9)	218.2	1		
Pretax margin (%)	61.3	6.6	(1.9)	4.9	4		
Vet profit margin (%)	47.1	4.2	(2.4)	3.2	3		
nterest cover (x)	nm	nm	nm	nm	I		
Effective tax rate (%)	22.0	20.0	20.0	20.0	20		
	67.6	40.7	nm	65.3	5		
Dividend payout (%)	67.6 13	40.7 40	nm 39	65.3 35			
					5		

Source: Company, AmInvestment Bank Bhd estimates

## DISCLOSURE AND DISCLAIMER

This report is prepared for information purposes only and it is issued by AmInvestment Bank Berhad ("AmInvestment") without regard to your individual financial circumstances and objectives. Nothing in this report shall constitute an offer to sell, warranty, representation, recommendation, legal, accounting or tax advice, solicitation or expression of views to influence any one to buy or sell any real estate, securities, stocks, foreign exchange, futures or investment products. AmInvestment recommends that you evaluate a particular investment or strategy based on your individual circumstances and objectives and/or seek financial, legal or other advice on the appropriateness of the particular investment or strategy.

The information in this report was obtained or derived from sources that AmInvestment believes are reliable and correct at the time of issue. While all reasonable care has been taken to ensure that the stated facts are accurate and views are fair and reasonable, AmInvestment has not independently verified the information and does not warrant or represent that they are accurate, adequate, complete or up-to-date and they should not be relied upon as such. All information included in this report constituteAmInvestment's views as of this date and are subject to change without notice. Notwithstanding that, AmInvestment has no obligation to update its opinion or information in this report. Facts and views presented in this report may not reflect the views of or information known to other business units of AmInvestment's affiliates and/or related corporations (collectively, "AmBank Group").

This report is prepared for the clients of AmBank Group and it cannot be altered, copied, reproduced, distributed or republished for any purpose without AmInvestment's prior written consent. AmInvestment, AmBank Group and its respective directors, officers, employees and agents ("Relevant Person") accept no liability whatsoever for any direct, indirect or consequential losses, loss of profits and/or damages arising from the use or reliance of this report and/or further communications given in relation to this report. Any such responsibility is hereby expressly disclaimed.

AmInvestment is not acting as your advisor and does not owe you any fiduciary duties in connection with this report. The Relevant Person may provide services to any company and affiliates of such companies in or related to the securities or products and/or may trade or otherwise effect transactions for their own account or the accounts of their customers which may give rise to real or potential conflicts of interest.

This report is not directed to or intended for distribution or publication outside Malaysia. If you are outside Malaysia, you should have regard to the laws of the jurisdiction in which you are located.

If any provision of this disclosure and disclaimer is held to be invalid in whole or in part, such provision will be deemed not to form part of this disclosure and disclaimer. The validity and enforceability of the remainder of this disclosure and disclaimer will not be affected.